Absorbed Organ Doses Research Articles

Comparison of Neutron Organ and Effective Dose Coefficients for PIMAL Stylized Phantoms in Bent Postures in Cranial and Caudal Irradiation Geometries.

Radiation dose estimations in the human body are performed using computational reference phantoms, which are anatomical representations of the human body. In previous studies, dose reconstructions have been performed focusing primarily on phantoms in an upright posture, which limits the accuracy of the dose estimations for postures observed in realistic work settings. In this work, the International Commission on Radiological Protection (ICRP) Publication 103 recommendations for monoenergetic neutron plane sources directed downward from above the head (cranial) and upward from below the feet (caudal) for adult female and male reference phantoms were used to calculate organ absorbed and effective dose coefficients. The Phantom with Moving Arms and Legs (PIMAL) and the Monte Carlo N-Particle (MCNP) radiation transport code were used to compute organ-absorbed dose and effective dose coefficients for the upright, half-bent (45°), and full-bent (90°) phantom postures. The doses calculated for each of the articulated positions were compared to those calculated for the upright posture by computing the ratios of the coefficients (45°/upright and 90°/upright). These ratios were used to assess the effectiveness of upright phantoms in providing a comparable estimate when conducting dose estimations and dose reconstructions for articulated positions. This work compiling neutron cranial and caudal posture-specific dose coefficients completes the series of dose coefficients computed for posture-specific ICRP Publication 116 irradiation geometries for monoenergetic photons and neutrons, in addition to cranial and caudal monoenergetic photons. Results reported demonstrated that organ-absorbed dose coefficients for most of the organs in the CRA and CAU irradiation geometries were significantly higher for the bent phantoms than for the upright phantom. Since the upright phantom underestimates the organ-absorbed dose, this demonstrates the impact of posture while performing dose calculations. Organ doses reported in past neutron dose coefficient data were found to omit effects from neutron resonances at energies of 0.435, 1.0, and 3.21 MeV from 16O in tissue. Reported data notes as high as 60% underestimation for neutron organ-absorbed doses, specifically at the neutron resonance energy region omitted by smoothing. Ongoing studies are examining the effect of resonances on reported neutron organ-absorbed dose coefficients in ICRP 116 geometries.

Effect of different phantom positions in lateral lumbar spine radiography on effective dose and absorbed dose to selected organs

This study aimed to investigate the different positioning of the patient in left and right lateral position during lumbar spine radiography and its effects on effective dose and absorbed dose for selected organs. The study was performed on a Siemens Multix/Vertix X-ray unit using Agfa's computer radiography system. Two anthropomorphic phantoms (PBU 60 and RS 113T) were imaged in both lateral projections with a tube voltage from 79 kV to 90 kV. The dose was measured with a DAP meter placed under the collimator of the X-ray unit. The effective dose and absorbed dose for selected organs were calculated using the Monte Carlo simulation programme PCXMC 2.0. Based on Monte Carlo simulation calculations, the results of effective dose on a PBU 60 phantom showed a decrease of 15.2%, while the decrease in effective dose on a RS 113T phantom was 14.2% in favour of the right lateral projection. An absorbed organ dose to selected organs showed a significant dose reduction for lymph nodes, pancreas, small intestine, spleen, and stomach in favour of this projection. Based on the results, we can conclude that right lateral projection should be the method of choice when imaging the lumbar spine in the lateral projection.

Patient-specific anatomical models for radioiodine dosimetry in treatment of hyperthyroidism: is it necessary?

To investigate the necessity of patient-specific dosimetry calculations using individualized models for hyperthyroid patients treated with radioactive iodine (RAI). This treatment modality was considered to be safe and effective; however, a recent publication indicated associations between greater organ-absorbed doses of RAI and risk of cancer death. Ten patient-specific models which ranged in size were used (from 152.5 to 184cm in height and from 44 to 88kg in mass). The time-integrated activity coefficients (TIAC) were evaluated from the 2017 Leggett's model assuming 24h radioactive iodine uptakes (RAIU) of 30, 50, 70, and 90% and two intake routes for normal uptake (ingestion and injection). A set of 131 I S factors (mGy MBq-1 h-1 ) from the patient-specific phantoms including 12 source regions were provided in this study. These S factors were used together with the new TIACs to present dose coefficients. The MC-based patient-specific S factors were compared with the ICRP standard data and the variation ranges (%) of (-65, +210) and (-57, +193) were reported for self and cross S factors, respectively. However, for self S factors, those intervals were reduced to (-8.3, +4.6) when mass correction was applied. Moreover, variations on organ dose coefficients were evaluated and the thyroid contributions were also assessed for 24h RAIU of 30, 50, 70, and 90%. Considering that the thyroid contribution to adjacent normal organs is high and the variations on cross dose coefficients are also considerable, variations (%) on normal organ doses were estimated to be up to (-63, +132), with a planned thyroid absorbed dose of 150Gy. Given the large variations on organ doses, the standard data are not an appropriate substitute for patient-specific data. Particularly, when accurate patient-specific dose estimation is a serious concern in RAI treatment (RAIT) for nuclear medicine practitioners. However, acquiring computed tomography (CT) images for patient-specific modeling will impose additional radiation dose to patients. It was concluded that CT imaging limited to the region from skull base to mid thorax (i.e., for organs with RAIT doses of >~50mGy with a dose of 150Gy prescribed to the thyroid) may be suggested and is clinically relevant because the normal organ dose increments are not greater than 10%.

ESTIMATION OF PHOTON ENERGY AND DIRECTION DISTRIBUTIONS AT JAPANESE NUCLEAR POWER PLANTS BASED ON LITERATURE SURVEY FOR J-EPISODE STUDY.

In order to reconstruct organ-absorbed dose from recorded dose for risk estimation in nuclear worker cohort, the preceding study of the International Agency for Research on Cancer (IARC) 15-Country Collaborative Study estimated the organ dose conversion factor from the recorded dose of Hp(10) under the assumption that on average, in the nuclear power plants (NPPs), 10% of the dose received by workers was due to photon energies ranging from 100 to 300 keV and 90% from photon energies ranging from 300 to 3000 keV, with the average geometry being 50% in the antero-posterior geometry and 50% in the isotropic geometry. Similar examination was conducted at the Japanese Epidemiological Study on Low-Dose Radiation Effects (J-EPISODE).Literature survey disclosed that Japanese electric power companies had jointly conducted the research on energy distribution and incidence direction distribution of gamma rays in working environments during periodical inspection and maintenance as well as during operation in the 1980s. The analysis of the survey results on photon energy and geometry distribution of Japanese NPPs demonstrated appropriateness in applying the IARC study assumption for nuclear workers in Japan and reconstructing organ-absorbed dose in the J-EPISODE. These results in Japan also provide strong evidence to support the robustness and generality of the IARC study assumption, which was estimated based on the judgment of experts at nuclear facilities around the world.

Evaluation of Radiation Doses in Pediatric Patients Undergoing Conventional Chest X-ray Examination.

This work deals with the evaluation of radiation doses from chest x rays for 240 male and female pediatric patients selected randomly from four Palestinian hospitals. The patient population was divided into five age groups: Newborn, 1, 5, 10, and 15 y old. Doses were theoretically calculated by using Monte Carlo based codes: CALDOSE-X5 and PCXMC-2.0. Patients' data and type of radiographic systems used as well as exposure factors were provided by the administrations of the selected hospitals. Absorbed organ doses from AP and PA projections were evaluated for 76 pediatric patients selected from one hospital in East Jerusalem. The highest mean organ dose for these patients was 0.085 mGy to the breast in AP projection. Effective doses were estimated for the five age groups for all patients. The highest average effective dose was found for patients in the age group of 10 y and was about 0.13 mSv, while the lowest average effective dose was found for the 5-y age group, about 0.06 mSv. The mean effective dose for all investigated patients in the five age categories was about 0.08 mSv. Variations in effective doses for the same age group and x-ray examination among involved hospitals are remarkable.

Age-dependent dose calculations for common PET radionuclides and brain radiotracers in nonhuman primate computational models.

The combination of nonhuman primates (NHPs) with the state-of-the-art molecular imaging technologies allows for within-subject longitudinal research aiming at gaining new insights into human normal and disease conditions and provides an ideal foundation for future translational studies of new diagnostic tools, medical interventions, and therapies. However, radiation dose estimations for nonhuman primates from molecular imaging probes are lacking and are difficult to perform experimentally. The aim of this work is to construct age-dependent NHP computational model series to estimate the absorbed dose to NHP specimens in common molecular imaging procedures. A series of NHP models from baby to adult were constructed based on nonuniform rational B-spline surface (NURBS) representations. Particle transport was simulated using Monte Carlo calculations to estimate S-values from nine positron-emitting radionuclides and absorbed doses from PET radiotracers. Realistic age-dependent NHP computational model series were developed. For most source-target pairs in computational NHP models, differences between C-11 S-values were between -13.4% and -8.8%/kg difference in body weight while differences between F-18 S-values were between -12.9% and -8.0%/kg difference in body weight. The absorbed doses of 11 C-labeled brain receptor substances, 18 F-labeled brain receptor substances, and 18 F-FDG in the brain ranged within 0.047-0.32mGy/MBq, 0.25-1.63mGy/MBq, and 0.32-2.12mGy/MBq, respectively. The absorbed doses to organs are significantly higher in the baby NHP model than in the adult model. These results can be used in translational longitudinal studies to estimate the cumulated absorbed organ doses in NHPs at various ages.

18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients.

The widespread use of gallium-68-labelled somatostatin analogue (SSA) PET, the current standard for somatostatin receptor (SSTR) imaging, is limited by practical and economic challenges that could be overcome by a fluorine-18-labelled alternative, such as the recently introduced [18F]AlF-NOTA-octreotide ([18F]AlF-OC). This prospective trial aimed to evaluate safety, dosimetry, biodistribution, pharmacokinetics and lesion targeting of [18F]AlF-OC and perform the first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour (NET) patients. Six healthy volunteers and six NET patients with a previous clinical [68Ga]Ga-DOTATATE PET were injected with an IV bolus of 4MBq/kg [18F]AlF-OC. Healthy volunteers underwent serial whole-body PET scans from time of tracer injection up to 90min post-injection, with an additional PET/CT at 150 and 300min post-injection. In patients, a 45-min dynamic PET was acquired and three whole-body PET scans at 60, 90 and 180min post-injection. Absorbed organ doses and effective doses were calculated using OLINDA/EXM. Normal organ uptake (SUVmean) and tumour lesion uptake (SUVmax and tumour-to-background ratio (TBR)) were measured. A lesion-by-lesion analysis was performed and the detection ratio (DR), defined as the fraction of detected lesions was determined for each tracer. [18F]AlF-OC administration was safe and well tolerated. The highest dose was received by the spleen (0.159 ± 0.062mGy/MBq), followed by the urinary bladder wall (0.135 ± 0.046mGy/mBq) and the kidneys (0.070 ± 0.018mGy/MBq), in accordance with the expected SSTR-specific uptake in the spleen and renal excretion of the tracer. The effective dose was 22.4 ± 4.4μSv/MBq. The physiologic uptake pattern of [18F]AlF-OC was comparable to [68Ga]Ga-DOTATATE. Mean tumour SUVmax was lower for [18F]AlF-OC (12.3 ± 6.5 at 2h post-injection vs. 18.3 ± 9.5; p = 0.03). However, no significant differences were found in TBR (9.8 ± 6.7 at 2h post-injection vs. 13.6 ± 11.8; p = 0.35). DR was high and comparable for both tracers (86.0% for [68Ga]Ga-DOTATATE vs. 90.1% for [18F]AlF-OC at 2h post-injection; p = 0.68). [18F]AlF-OC shows favourable kinetic and imaging characteristics in patients that warrant further head-to-head comparison to validate [18F]AlF-OC as a fluorine-18-labelled alternative for gallium-68-labelled SSA clinical PET. Clinicaltrials.gov : NCT03883776, EudraCT: 2018-002827-40.

Dose comparative study between two different 3D mobile intra-operative systems

3D imaging devices, when coupled to an image guided surgery system, allow for a more precise surgical approach than classical C-arms. Nevertheless, the exposure to radiation of both patient and staff remains a concern and therefore the choice of imaging device plays an important role. Two 3D imaging systems, an imaging mobile device with an O-ring geometry and an imaging mobile device with a C-arm geometry, have been compared in terms of absorbed doses to organs as well as ambient dose equivalent. Absorbed organ doses were evaluated for thoracic and pelvic examinations using TLDs placed within a CIRS anthropomorphic phantom representing an adult woman. Equivalent ambient dose measurements were performed at various positions in the room around the X-ray system using a calibrated dose rate meter. Results suggest that the O-ring system exposes both patient and staff to higher levels of radiation than the C-arm system. Indeed, organ absorbed doses were found to be 3.5 and 1.7 higher for the O-ring system than for the C-arm system for the same thoracic and pelvic explorations respectively. Concerning the ambient dose equivalent, it was found that for a single 3D image acquisition at a radial distance of one meter from the isocentre, measurements for the O-ring system were approximately 30% larger than the C-arm system.

3D Assessment of Endodontic Lesions with a Low-Dose CBCT Protocol.

Background: Cone beam computed tomography (CBCT) is often used in different fields of dental science, especially in complex anatomical districts like the endodontic one. The aim of this study is to propose a low-dose CBCT protocol useful in cases of endodontic lesions. Methods: The device used was a MyRay Hyperion X9-11x5; the low dose setting of the machine was 90 Kv, 27 mAs, CTDI/Vol 2.89 mGy. The absorbed organ doses have been evaluated with an anthropomorphic phantom loaded with thermoluminescent dosimeters positioned at the level of sensitive organs like brain, bone marrow, salivary glands, thyroid, esophagus, oral mucosa, extrathoracic airways, and lymph nodes. Equivalent and effective doses have been calculated; the last one has been calculated using the recommendations approved by the Main Commission of ICRP (International Commission Radiological Protection) in March 2007. For the assessment of image quality, five senior clinicians, independent and experienced clinicians, were asked to state if CBCT scans were accurate enough to assess endodontic lesions. Results: The use of a low-dose CBCT acquisition produced the lowest organ dose (5.01 microSv) at the level of the esophagus. Image quality has been considered accurate enough for endodontic diagnostic needs. Conclusions: CBCT low-dose protocol can be used over the standard one in endodontic special cases because it provides a significantly lower radiation dose to the patients while ensuring good image quality. However, further studies are necessary to evaluate the opportunity of low-dose CBCT exams in endodontic clinical practice.

Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy.

Aim: The objective of this study was to estimate the absorbed doses to the normal organs and tumor lesions in metastatic castration-resistant prostate cancer (mCRPC) patients treated with indigenously developed 177Lu-PSMA-617 that could establish optimal treatment protocol with minimum risk to the dose-limiting organs. Furthermore, attempt was also made to compare radiation absorbed doses for normal organs and tumor lesions in subsequent cycles of 177Lu-PSMA-617 peptide receptor radioligand therapy (PRLT) in the same group of patients during the course of treatment. Methods: A total of 30 patients of proven mCRPC were enrolled for this prospective study. These patients received up to 5 cycles of treatment with 177Lu-PSMA-617 PRLT (1 cycle for 13 patients, 2 cycles for 9 patients, 3 cycles for 3 patients, and 5 cycles for 5 patients), at 11-12-week intervals between the two successive therapies. The patients underwent postadministration whole-body scintigraphy at five time points: 0.5 (prevoid), 2, 12, 24, and 72/96 h (postvoid). From time-activity curves generated by drawing regions of interests on the images, number of disintegrations was determined. Tumor masses were estimated from pretherapeutic 68Ga-PSMA-11 positron emission tomography-computed tomography images. Absorbed doses for organs and tumors were calculated using OLINDA 2.0 software. Results: The average activity of 177Lu-PSMA-617 (mean ± SD) administered per patient per cycle was 4.94 ± 0.45 GBq. The mean absorbed organ doses (mean ± SD) from first therapy cycle in Gy/GBq were as follows: kidneys 0.52 ± 0.16, spleen 0.17 ± 0.07, liver 0.08 ± 0.05, salivary glands 0.53 ± 0.30, lacrimal glands 1.45 ± 0.85, nasal mucosa membrane 0.46 ± 0.19, urinary bladder 0.23 ± 0.02, and bone marrow 0.04 ± 0.03. The mean effective dose for whole body from first therapy cycle was 0.05 ± 0.03 Sv/GBq. Among all the normal organs, lacrimal glands received the highest absorbed dose. The median dose for all lesions, bone lesions, lymph nodes, primary site, liver lesion, lung lesion, and soft tissue deposit from first therapy cycle was determined to be 4.17, 4.23, 3.96, 4.36, 10.27, 0.78, and 4.68 Gy/GBq respectively. Absorbed doses received by the normal organs in five consecutive cycles follow three different trends, (a) for kidneys, salivary glands, and nasal mucous membrane, absorbed doses increased from first therapy cycle to second therapy cycle and then slowly decreased in subsequently therapy cycles; (b) for spleen, liver, and lacrimal glands, absorbed doses decreased with the successive therapy cycles; and (c) in case of bone marrow, bladder, and whole body, mean absorbed dose almost remained constant in each therapy cycle. Absorbed doses to the lesions gradually decreased with increase of the number of therapy cycles. Conclusions: The organ and tumor absorbed doses of 177Lu-PSMA-617 in mCRPC patients were found to be comparable to the data reported in the literature. The highest absorbed organ dose was observed in lacrimal glands and being a dose limiting organ, a cumulative activity up to 32.5 GBq (878 mCi) of 177Lu-PSMA-617 in 4-5 therapy cycles appears safe and feasible to achieve full therapeutic window.

CONVERSION FACTOR FROM DOSEMETER READING TO AIR KERMA FOR NUCLEAR WORKER USING ANTHROPOMORPHIC PHANTOM FOR FURTHER CONVERSION FROM AIR KERMA TO ORGAN-ABSORBED DOSE.

Estimation of cancer risk based on the organ-absorbed dose is underway for the Japanese Epidemiological Study on Low-Dose Radiation Effects (J-EPISODE). The reconstruction method for the organ-absorbed dose follows the approach adopted in the IARC 15-Country Collaborative Study, which examined the dosemeter response to photon exposure for the old film badge (FB) type, a multi-element FB and a thermoluminescence dosemeter. Until 2000, the dosemeters used in Japan were almost the same in the IARC study, so IARC study data could be used as they were. However, since 2000, the type of dosemeter has been replaced with active personal dosemeters (hereafter called electronic personal dosemeters), radio-photoluminescent glass dosemeters (Glass badge) and optically stimulated luminescence dosemeters (Luminess badge). Hence, it was necessary to collect these data again. A dosemeter response experiment was conducted using a device that irradiated an anthropomorphic phantom in the Japan Atomic Energy Agency calibration laboratories. The aim of the paper is to provide a conversion factor from reading in terms of Hp(10) to air kerma for realistic conditions for further conversion from air kerma to organ-absorbed dose. The obtained dosemeter responses for the dosemeter types currently used in Japan were consistent with those in the IARC study. These data will be utilized for J-EPISODE in reconstructing the organ-absorbed dose.

OPTIMAL COLLIMATION SIGNIFICANTLY IMPROVES LUMBAR SPINE RADIOGRAPHY.

To determine the influence of optimal collimation during lumbar spine radiography on radiation dose and image quality. 110 lumbar spine patients were split into two groups-the first imaged with standard collimation and the second with optimal collimation. Body mass index, image field size, exposure conditions and dose area product were measured. Effective and absorbed organ doses were calculated. Image quality was assessed. Optimal collimation reduced the primary field by up to 40%. The effective dose was reduced by 48% for the AP projection, while no differences were found for the LAT projection due to incorrect positioning of the central beam with standard collimation. The absorbed dose to selected radiosensitive organs decreased by 41 and 10% in the AP and LAT projections, respectively. Image quality for the LAT projection improved by 24% and maintained for the AP projection. Optimal collimation in lumbar spine imaging significantly influences patient exposure to radiation.

Monte Carlo simulation of non-target organ doses and radiation-induced secondary cancer risk in Tanzania from radiotherapy of nasopharyngeal by using Co-60 source

A few studies have reported the risks of secondary cancer in patients after radiation therapy in Tanzanian hospitals. This study was designed to assess non-target organ doses from Co-60 teletherapy for patients with nasopharyngeal cancer and to estimate the risk of radiation-induced secondary cancer. Specific organ-absorbed doses were evaluated in anatomically realistic 15-year-old and adult male phantoms based on Monte Carlo simulation. The assessed organ doses were used to calculate the lifetime secondary cancer risks in non-target organs according to the BEIR VII risk models. Survival information and the baseline cancer risks were associated with statistical data for the Tanzanian population. The average absorbed doses in non-target organs depended heavily on the distance from the target isocentre and patient's age. Organs near the tumour target, such as the salivary glands, brain, thyroid glands, eye bulb and oesophagus, received very high absorbed doses. The absorbed doses decreased exponentially towards the testis and prostate which are far from the tumour target. The highest received absorbed doses in non-target organs were due to the leakage in the gantry head and scattered radiation from collimator and inside the patient body. The absorbed doses were higher for young patients than in adults because of the larger body area exposed to high-dose radiation. The lifetime attributed risks for all organs considered were relatively lower than the baseline cancer risks. Results can help provide future database about radiation-induced second primary cancer incidence after Co-60 external beam radiation therapy for nasopharyngeal cancer in Tanzania and in many other developing countries.

Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect.

Expression levels of biomarkers are generally unknown at initial diagnosis. The development of theranostic probes that do not rely on biomarker availability would expand therapy options for cancer patients, improve patient selection for nanomedicine and facilitate treatment of inoperable patients or patients with acquired therapy resistance. Herein, we report the development of star polymers, also known as nanostars, that allow for molecular imaging and/or endoradiotherapy based on passive targeting via the enhanced permeability and retention (EPR) effect.Methods: We synthesised a star copolymer, consisting of 7-8 centre-cross-linked arms that were modified with Gd3+ for magnetic resonance imaging (MRI), and functionalised either with 89Zr for in vivo quantification and positron emission tomography (PET) imaging, or with 177Lu for endoradiotherapy. 1H longitudinal relaxivities were determined over a continuum of magnetic field strengths ranging from 0.24 mT - 0.94 T at 37 °C (nuclear magnetic relaxation dispersion (NMRD) profile) and T1-weighted MRI contrast enhancement was visualized at 3 T and 7 T. PET imaging and ex vivo biodistribution studies were performed in mice bearing tumours with high EPR (CT26) or low EPR (BxPC3) characteristics. Therapy studies were performed in mice with high EPR tumours and mean absorbed organ doses were estimated for a standard human model.Results: The star copolymer with Gd3+ displayed a significantly superior contrast enhancement ability (T1 = 0.60 s) compared to the standard clinical contrast agent Gadovist (T1 = 1.0 s). Quantification of tumour accumulation using the radiolabelled nanostars in tumour-bearing mice demonstrated an exceptionally high uptake in tumours with high EPR characteristics (14.8 - 21.7 %ID/g). Uptake of the star polymers in tumours with low EPR characteristics was significantly lower (P<0.001), suggesting passive tumour accumulation of the nanostars via the EPR effect. Survival of mice treated with high dose 177Lu-labelled star polymers was significantly higher than survival of mice treated with lower therapy doses or control mice (P=0.001), demonstrating the utility of the 177Lu-labelled star polymers as platforms for endoradiotherapy.Conclusion: Our work highlights the potential of star polymers as probes for the molecular imaging of cancer tissue or for the passive delivery of radionuclides for endoradiotherapy. Their high functionalisability and high tumour accumulation emphasises their versatility as powerful tools for nanomedicine.

Trends in Estimated Thyroid, Salivary Gland, Brain, and Eye Lens Doses From Intraoral Dental Radiography Over Seven Decades (1940 TO 2009).

The purpose of this study is to support retrospective dose estimation for epidemiological studies by providing estimates of historical absorbed organ doses to the brain, lens of the eye, salivary glands, and thyroid from intraoral dental radiographic examinations performed from 1940 to 2009. We simulated organ doses to an adult over 10 y time periods from 1940 to 2009, based on commonly used sets of x-ray machine settings collected from the literature. Simulations to estimate organ dose were performed using personal computer x-ray Monte Carlo software. Overall, organ doses were less than 1 mGy for a single intraoral radiograph for all decades. From 1940 to 2009, doses to the brain, eye lens, salivary glands, and thyroid decreased by 86, 96, 95, and 89%, respectively. Of these four organs, the salivary glands received the highest doses, with values decreasing from about 0.23 mGy in the 1940s to 0.025 mGy in the 2000s for a single intraoral radiograph. Based on simulations using collected historical data on x-ray technical parameters, improvements in technology and optimization of the technical settings used to perform intraoral dental radiography have resulted in a decrease in absorbed dose to the brain, eye lens, salivary glands, and thyroid over the period from 1940 to 2009.

Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients.

Targeting cancer-associated fibroblasts (CAFs) has become an attractive goal for diagnostic imaging and therapy because they can constitute as much as 90% of a tumor mass. The serine protease fibroblast activation protein (FAP) is overexpressed selectively in CAFs, drawing interest in FAP as a stromal target. The quinoline-based FAP inhibitor (FAPI) PET tracer 68Ga-FAPI-04 has been previously shown to yield high tumor-to-background ratios (TBRs) in patients with various cancers. Recent developments toward an improved compound for therapeutic application have identified FAPI-46 as a promising agent because of an increased tumor retention time in comparison with FAPI-04. Here, we present a PET biodistribution and radiation dosimetry study of 68Ga-FAPI-46 in cancer patients. Methods: Six patients with different cancers underwent serial 68Ga-FAPI-46 PET/CT scans at 3 time points after radiotracer injection: 10 min, 1 h, and 3 h. The source organs consisted of the kidneys, bladder, liver, heart, spleen, bone marrow, uterus, and remainder of body. OLINDA/EXM software, version 1.1, was used to fit and integrate the kinetic organ activity data to yield total-body and organ time-integrated activity coefficients and residence times and, finally, organ-absorbed doses. SUVs and TBR were generated from the contoured tumor and source-organ volumes. Spheric volumes in muscle and blood pool were also obtained for TBR (tumor SUVmax/organ SUVmean). Results: At all time points, average SUVmax was highest in the liver. Tumor and organ SUVmean decreased over time, whereas TBRs in all organs but the uterus increased. The organs with the highest effective doses were bladder wall (2.41E-03 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red marrow (8.49E-04 mSv/MBq). The average effective total-body dose was 7.80E-03 mSv/MBq. Conclusion:68Ga-FAPI-46 PET/CT has a favorable dosimetry profile, with an estimated whole-body dose of 5.3 mSv for an administration of 200 MBq (5.4 mCi) of 68Ga-FAPI-46 (1.56 ± 0.26 mSv from the PET tracer and 3.7 mSv from 1 low-dose CT scan). The biodistribution study showed high TBRs increasing over time, suggesting high diagnostic performance and favorable tracer kinetics for potential therapeutic applications.

First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer.

Besides PSMA, prostate cancer cells also express gastrin-releasing peptide receptor (GRPr) which is therefore a promising target for theranostic approaches. The high affinity GRPr antagonist RM2 can be labeled with beta-emitting radiometals for therapeutic purposes. The aim of this study was to calculate absorbed doses for critical organs and tumor lesions for [177Lu]Lu-RM2 therapy administered in a group of metastatic castration-resistant prostate cancer (mCRPC) patients who had insufficient PSMA expression or showed lower PSMA accumulation after previous cycles of [177Lu]Lu-PSMA-617 therapy. Thirty-five patients suffering from mCRPC without further treatment options for approved therapies were examined with [68Ga]Ga-RM2-PET/CT. Out of these, 4 patients (mean age 68years) were treated with [177Lu]Lu-RM2; two of these also received a 2nd therapy cycle. Mean activity was 4.5 ± 0.9GBq. For dosimetry, patients underwent planar WB-scintigraphy and SPECT/CT imaging of the upper and lower abdomen at approximately 1, 24, 48, and 72h p.i. along with blood sampling. Absorbed doses for kidneys, pancreas, liver, spleen, gallbladder wall, and tumor lesions were derived based on quantitative SPECT/CT according to RADAR dosimetry scheme; individual organ masses were extracted from CT. Absorbed dose to bone marrow was calculated based on serial whole-body images and blood sampling according to the EANM guideline. Therapy was well tolerated by all patients and no side effects were observed. An increased uptake in tumor lesions and the pancreas was seen within the first 1h. Mean absorbed organ doses were 1.08 ± 0.44Gy/GBq in the pancreas, 0.35 ± 0.14Gy/GBq in the kidneys, 0.05 ± 0.02Gy/GBq in the liver, 0.07 ± 0.02Gy/GBq in the gallbladder wall, 0.10 ± 0.06Gy/GBq in the spleen, and 0.02 ± 0.01Gy/GBq for the red bone marrow. The mean dose for tumor lesions was 6.20 ± 3.00Gy/GBq. Application of GRPr antagonist [177Lu]Lu-RM2 is suitable for targeted radiotherapy of mCRPC as it shows high tumor uptake and rapid clearance from normal organs. Absorbed doses in tumor lesions are therapeutically relevant. The critical organ receiving the highest absorbed dose was the pancreas. Results suggest that the activity administered for each cycle could be increased to maximize the absorbed dose of tumors and metastases.

Size-specific dose estimations for pediatric chest, abdomen/pelvis and head CT scans with the use of GATE

PurposeThe purpose of this study is to create an organ dose database for pediatric individuals undergoing chest, abdomen/pelvis, and head computed tomography (CT) examinations, and to report the differences in absorbed organ doses, when anatomical differences exist for pediatric patients. MethodsThe GATE Monte Carlo (MC) toolkit was used to model the GE BrightSpeed Elite CT model. The simulated scanner model was validated with the standard Computed Tomography Dose Index (CTDI) head phantom. Twelve computational models (2.1–14 years old) were used. First, contributions to effective dose and absorbed doses per CTDIvol and per 100 mAs were estimated for all organs. Then, doses per CTDIvol were correlated with patient model weight for the organs inside the scan range for chest and abdomen/pelvis protocols. Finally, effective doses per dose-length product (DLP) were estimated and compared with the conventional conversion k-factors. ResultsThe system was validated against experimental CTDIw measurements. The doses per CTDIvol and per 100 mAs for selected organs were estimated. The magnitude of the dependency between the dose and the anatomical characteristics was calculated with the coefficient of determination at 0.5–0.7 for the internal scan organs for chest and abdomen/pelvis protocols. Finally, effective doses per DLP were compared with already published data, showing discrepancies between 13 and 29% and were correlated strongly with the total weight (R2 > 0.8) for the chest and abdomen protocols. ConclusionsBig differences in absorbed doses are reported even for patients of similar age or same gender, when anatomical differences exist on internal organs of the body.

Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism

Radioactive iodine (RAI) has been used extensively to treat hyperthyroidism since the 1940s. Although widely considered a safe and effective therapy, RAI has been associated with elevated risks of total and site-specific cancer death among patients with hyperthyroidism. To determine whether greater organ- or tissue-absorbed doses from RAI treatment are associated with overall and site-specific cancer mortality in patients with hyperthyroidism. This cohort study is a 24-year extension of the multicenter Cooperative Thyrotoxicosis Therapy Follow-up Study, which has followed up US and UK patients diagnosed and treated for hyperthyroidism for nearly 7 decades, beginning in 1946. Patients were traced using records from the National Death Index, Social Security Administration, and other resources. After exclusions, 18 805 patients who were treated with RAI and had no history of cancer at the time of the first treatment were eligible for the current analysis. Excess relative risks (ERRs) per 100-mGy dose to the organ or tissue were calculated using multivariable-adjusted linear dose-response models and were converted to relative risks (RR = 1 + ERR). The current analyses were conducted from April 28, 2017, to January 30, 2019. Mean total administered activity of sodium iodide I 131 was 375 MBq for patients with Graves disease and 653 MBq for patients with toxic nodular goiter. Mean organ or tissue dose estimates ranged from 20 to 99 mGy (colon or rectum, ovary, uterus, prostate, bladder, and brain/central nervous system), to 100 to 400 mGy (pancreas, kidney, liver, stomach, female breast, lung, oral mucosa, and marrow), to 1.6 Gy (esophagus), and to 130 Gy (thyroid gland). Site-specific and all solid-cancer mortality. A total of 18 805 patients were included in the study cohort, and the mean (SD) entry age was 49 (14) years. Most patients were women (14 671 [78.0%]), and most had a Graves disease diagnosis (17 615 [93.7%]). Statistically significant positive associations were observed for all solid cancer mortality (n = 1984; RR at 100-mGy dose to the stomach = 1.06; 95% CI, 1.02-1.10; P = .002), including female breast cancer (n = 291; RR at 100-mGy dose to the breast = 1.12; 95% CI, 1.003-1.32; P = .04) and all other solid cancers combined (n = 1693; RR at 100-mGy dose to the stomach = 1.05; 95% CI, 1.01-1.10; P = .01). The 100-mGy dose to the stomach and breast corresponded to a mean (SD) administered activity of 243 (35) MBq and 266 (58) MBq in patients with Graves disease. For every 1000 patients with hyperthyroidism receiving typical doses to the stomach (150 to 250 mGy), an estimated lifetime excess of 19 (95% CI, 3-40) to 32 (95% CI, 5-66) solid cancer deaths could occur. In RAI-treated patients with hyperthyroidism, greater organ-absorbed doses appeared to be modestly positively associated with risk of death from solid cancer, including breast cancer. Additional studies are needed of the risks and advantages of all major treatment options available to patients with hyperthyroidism.

LUMBAR SPINE RADIOGRAPHY: LOWER ORGAN DOSE WITH THE USE OF PA PROJECTION.

The purpose of the research was to determine the effect of the posteroanterior (PA) patient position in lumbar spine imaging on effective dose and the absorbed organ dose. The study was performed on 100 patients that were referred to the lumbar spine radiography that were divided into two equal groups of 50. Body Mass Index, Dose Area Product (DAP), exposure index (EXI), tube time-current (mAs), image field size and the source-patient distance were acquired for each patient. The entrance surface dose (ESD), the effective dose and the absorbed organ doses were calculated. There was no statistically significant difference in the BMI and EXI between the AP and PA projection. The results showed a significant reduction of ESD by 33% and the effective dose by 53% when the PA projection was used. Furthermore, there was a 64% average reduction of the absorbed organ doses to the selected organs.